Immuno-Oncology: New Products Provide Growth And Value

For now we think large cap biopharmas that pay dividends are the place to be for safety and modest growth until the technicals improve with small and mid-caps in the sector.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.